🟢 Alzamend Neuro is trading 7.09% up in pre-market — no clear catalyst identified

Alzamend Neuro is trading at $1.51, up 7.09% in pre-market, with no cause identified for the November 9 rise.

• No new company-specific announcement was identified; the latest press releases date to September and August.
• Alzamend Neuro previously said Phase 1/2A data would be presented at a November 14–18 neuroscience meeting; that earlier announcement does not establish a cause for this move.
• Broader market indicators were mixed and do not clearly explain the gain.